AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
HEIDELBERG, Germany, Nov 11 (Bernama) -- In a world where patients with CDKL5 deficiencies can suffer 40 to 60 epileptic seizures a day, a contract biopharmaceutical manufacturer and a parent-founded foundation will partner on early-stage messenger RNA development to find a long-term treatment for the rare neurodevelopmental disease.
With few RNA-based programs in development for rare diseases, Child’s Cure Genetic Research and AGC Biologics will collaborate to identify a viable path for a new mRNA therapeutic that mimics the protein made by the CDKL5 gene. The intent of the protein-sustaining treatment is to reduce seizures, improve neurological development, and help patients—many of whom are babies and young children—gain control from debilitating symptoms that impede their health and potential.